Product Details
PMS-Cinacalcet
Cinacalcet60 mg
Tablet
DIN/PIN/NPN
02517612
Manufacturer
Pharmascience Inc.
Formulary Listing Date
2022-09-29
Unit Price
18.5900
Amount MOH Pays
18.5900
Coverage Status
Off-Formulary Interchangeable Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
H05BX01
Interchangeable Products
DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
---|---|---|---|
02441632 | Teva-Cinacalcet | 18.5900 | 18.5900 |
02257149 | Sensipar | 21.9800 | 18.5900 |
02434547 | Mylan-Cinacalcet | 18.5900 | 18.5900 |
02481995 | M-Cinacalcet | 18.5900 | 18.5900 |
02480301 | Mar-Cinacalcet | 18.5900 | 18.5900 |
02500108 | Jamp Cinacalcet | 18.5900 | 18.5900 |
02478919 | Auro-Cinacalcet | 18.5900 | 18.5900 |
02452707 | Apo-Cinacalcet | 18.5900 | 18.5900 |
02517612 | PMS-Cinacalcet | 18.5900 | 18.5900 |
LU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Nephrology Treatments | Cinacalcet
For the treatment of severe hyperparathyroidism* in patients with chronic kidney disease who are on dialysis who meet the following criteria:
*Severe hyperparathyroidism is considered to be patients with PTH levels greater than 88 pmol/L confirmed on two laboratory tests for PTH taken at least 1 month apart. Exclusion Criteria: Initial Approval durations:
Duration of Approval: 1 year or to the estimated date of the procedure for those using for bridge therapy and awaiting surgery Renewals will be considered for patients who are not candidates for parathyroidectomy and who continue to benefit from therapy. Requests for renewals should include the patient’s PTH level. Renewals will NOT be considered for patients who have had a parathyroidectomy. |